Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars in Medicare Part B: CMS Weighing Payment Demonstration To Boost Uptake

Executive Summary

Agency cites possible demonstration in response to HHS Office of Inspector General report urging reimbursement reforms to spur greater use of biosimilars and lower costs for Medicare and beneficiaries.

You may also be interested in...



Lack Of Competition Equals Higher Drug Prices: HHS Analysis Is Slogan In Search Of Solutions

Findings could provide a basis for future policy interventions, the department says. Speeding generics and biosimilars would seem a natural outshoot of the conclusions, but the report does not contain any recommendations.

Medicare Part D Coverage For Humira Biosimilars Has Inspector General’s Attention

Office of Inspector General analysis could add momentum to reforms of the rebating system.

Medicare, Medicaid Drug Payment Models Get Designated Team At CMMI

CMS’ innovation center creates new division to test alternative payment models, including likely new approaches for accelerated approval drugs and multi-state outcomes-based payment arrangements for cell and gene therapy in Medicaid.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel